Lupin carves out consumer healthcare business

Mumbai: Global pharma major Lupin Limited, has announced the strategic carve-out of its consumer healthcare business, LupinLife Consumer Healthcare Ltd. (LCH), into a wholly owned subsidiary, effective July 1, 2025.

"This initiative aligns with the aspiration to establish a specialized consumer healthcare entity, with an enhanced focus on India's rapidly growing selfcare market," Lupin stated in its recent release.

Since its inception in 2017, LupinLife Consumer Healthcare has emerged as a strong over-the-counter (OTC) healthcare business with a portfolio of scientifically formulated brands such as Softovac, Beplex Forte, Corcium and Aptivate.

Anil Kaushal will lead the new independent entity as Chief Executive Officer. This restructuring will enable enhanced focus with targeted investments, leading to increased consumer impact, market expansion, and accelerated growth.

Speaking on the development, Nilesh Gupta, Managing Director, Lupin said, "This strategic move reinforces our mission of developing high-impact businesses that drive sustained value. LCH exemplifies our unwavering dedication to patient-centric care and service to consumers.”

Anil V Kaushal, CEO LupinLife Consumer Healthcare Ltd., commented, "This carve-out marks an exciting new chapter in our consumer healthcare journey. We are committed to offering world-class OTC products and wellness solutions for Indian consumers. LCH is well-positioned to scale with agility, innovate with intent, and expand access to wellness solutions across India.”

Read also: Lupin rolls out constipation drug Prucalopride in US after USFDA nod

Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. The company has a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women's health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally.

Read also: USFDA okays Lupin Prucalopride Tablets for chronic idiopathic constipation